Citius Oncology (CTOR) Competitors $0.65 -0.04 (-5.42%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. FHTX, MBX, ITOS, CRVS, YMAB, NVCT, OCGN, LFCR, GOSS, and CRGXShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Foghorn Therapeutics (FHTX), MBX Biosciences (MBX), iTeos Therapeutics (ITOS), Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Ocugen (OCGN), Lifecore Biomedical (LFCR), Gossamer Bio (GOSS), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Foghorn Therapeutics MBX Biosciences iTeos Therapeutics Corvus Pharmaceuticals Y-mAbs Therapeutics Nuvectis Pharma Ocugen Lifecore Biomedical Gossamer Bio CARGO Therapeutics Foghorn Therapeutics (NASDAQ:FHTX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends. Is FHTX or CTOR more profitable? Citius Oncology has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-357.53% N/A -30.98% Citius Oncology N/A -43.67%-9.74% Does the MarketBeat Community favor FHTX or CTOR? Foghorn Therapeutics received 40 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 64.06% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformFoghorn TherapeuticsOutperform Votes4164.06% Underperform Votes2335.94% Citius OncologyOutperform Votes1100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of FHTX or CTOR? 61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 9.1% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 4.6% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate FHTX or CTOR? Foghorn Therapeutics currently has a consensus price target of $13.17, suggesting a potential upside of 279.44%. Citius Oncology has a consensus price target of $3.00, suggesting a potential upside of 364.40%. Given Citius Oncology's higher probable upside, analysts clearly believe Citius Oncology is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor FHTX or CTOR? In the previous week, Foghorn Therapeutics had 3 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Foghorn Therapeutics and 0 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.87 beat Foghorn Therapeutics' score of 0.81 indicating that Citius Oncology is being referred to more favorably in the news media. Company Overall Sentiment Foghorn Therapeutics Positive Citius Oncology Very Positive Which has more volatility and risk, FHTX or CTOR? Foghorn Therapeutics has a beta of 3.16, suggesting that its share price is 216% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Which has stronger earnings and valuation, FHTX or CTOR? Citius Oncology has lower revenue, but higher earnings than Foghorn Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M8.54-$98.43M-$1.65-2.10Citius OncologyN/AN/A-$21.15MN/AN/A SummaryFoghorn Therapeutics beats Citius Oncology on 8 of the 15 factors compared between the two stocks. Remove Ads Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.22M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.6921.6317.68Price / SalesN/A222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book-2.945.776.373.94Net Income-$21.15M$142.01M$3.20B$247.45M7 Day Performance2.22%2.88%1.79%0.48%1 Month Performance-11.99%-13.93%-9.41%-7.08%1 Year PerformanceN/A-12.36%9.61%-0.35% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius OncologyN/A$0.65-5.4%$3.00+364.4%N/A$46.22MN/A0.00N/AGap DownFHTXFoghorn Therapeutics2.229 of 5 stars$3.68+7.0%$13.17+257.8%-44.1%$204.65M$22.60M-1.92120News CoverageMBXMBX Biosciences2.1489 of 5 stars$6.00-0.7%$37.25+520.8%N/A$201.88MN/A0.0036News CoverageGap DownITOSiTeos Therapeutics2.2494 of 5 stars$5.25-2.6%$25.75+390.5%-49.6%$200.52M$35M-1.6790Short Interest ↑Positive NewsGap DownCRVSCorvus Pharmaceuticals3.0382 of 5 stars$2.91+2.1%$15.67+438.4%+120.4%$198.28MN/A-3.1330YMABY-mAbs Therapeutics3.703 of 5 stars$4.28-5.7%$18.30+327.6%-64.1%$193.53M$87.69M-7.93150Short Interest ↓NVCTNuvectis Pharma2.7733 of 5 stars$8.24-0.1%$15.67+90.1%+48.7%$192.75MN/A-7.108Gap DownOCGNOcugen1.0525 of 5 stars$0.65-2.0%$6.33+876.2%-56.1%$189.46M$4.06M-3.6080Gap DownLFCRLifecore Biomedical1.828 of 5 stars$5.10-3.6%$8.00+56.9%+0.0%$188.83M$130.86M-9.11690High Trading VolumeGOSSGossamer Bio3.7757 of 5 stars$0.82+2.6%$7.75+844.4%-3.3%$186.46M$114.70M-2.56180Short Interest ↑CRGXCARGO Therapeutics2.8124 of 5 stars$4.03+0.2%$15.00+272.2%-77.1%$185.59MN/A-0.95116High Trading Volume Remove Ads Related Companies and Tools Related Companies Foghorn Therapeutics Competitors MBX Biosciences Competitors iTeos Therapeutics Competitors Corvus Pharmaceuticals Competitors Y-mAbs Therapeutics Competitors Nuvectis Pharma Competitors Ocugen Competitors Lifecore Biomedical Competitors Gossamer Bio Competitors CARGO Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTOR Stock Free CTOR Stock Alerts